MXPA03004427A - Analogos de acido graso para el tratamiento de desordenes inflamatorios y autoinmunes. - Google Patents
Analogos de acido graso para el tratamiento de desordenes inflamatorios y autoinmunes.Info
- Publication number
- MXPA03004427A MXPA03004427A MXPA03004427A MXPA03004427A MXPA03004427A MX PA03004427 A MXPA03004427 A MX PA03004427A MX PA03004427 A MXPA03004427 A MX PA03004427A MX PA03004427 A MXPA03004427 A MX PA03004427A MX PA03004427 A MXPA03004427 A MX PA03004427A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- fatty acid
- treatment
- relates
- acid analogues
- Prior art date
Links
- 235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
- 229930195729 fatty acid Natural products 0.000 title abstract 2
- 239000000194 fatty acid Substances 0.000 title abstract 2
- 150000004665 fatty acids Chemical class 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 102000003814 Interleukin-10 Human genes 0.000 abstract 2
- 108090000174 Interleukin-10 Proteins 0.000 abstract 2
- 229940076144 interleukin-10 Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 210000005087 mononuclear cell Anatomy 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Obesity (AREA)
Abstract
La presente invencion se refiere a analogos de acido graso de la formula general R1 - [xi - CH2]n - COOR2; donde R1 es un (C1-24)alqueno con uno o mas enlaces dobles y/o con uno o mas enlaces triples, y/o un (C1-24)alquino, y/o un (C1-24)alquilo, o un (C1-24)alquilo sustituido en una o varias posiciones con uno o mas compuestos seleccionados del grupo que comprende fluoruro, cloruro, hidroxi, (C1- 4) alcoxi, (C1-4) aiquiltio, (C2-5) aciloxi o (C1-4) alquilo, y donde R2 representa hidrogeno o (C1-4)alquilo, y donde n es un entero desde 1 hasta 12, y donde i es un numero non e indica la posicion relativa hacia COCR2, y donde xi, independientes una de otra, se seleccionan a partir del grupo que comprende O, S, SO, SO2, Se y CH2, y con la condicion de que al menos una de las xi no sea CH2, que puede ser usado para el tratamiento y/o prevencion de desordenes inflamatorios. Ademas, la invencion se refiere a metodos para incrementar la produccion endogena de interleucina-10 (1L-10) y suprimir la produccion de interleuccina-2 en celulas o tejidos de mamiferos. La invencion tambien se refiere a un metodo para inhibir la proliferacion de celulas mononucleares perifericas estimuladas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20006008A NO20006008L (no) | 2000-11-28 | 2000-11-28 | Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer |
| PCT/NO2001/000470 WO2002043728A1 (en) | 2000-11-28 | 2001-11-27 | Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA03004427A true MXPA03004427A (es) | 2004-05-04 |
Family
ID=19911849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA03004427A MXPA03004427A (es) | 2000-11-28 | 2001-11-27 | Analogos de acido graso para el tratamiento de desordenes inflamatorios y autoinmunes. |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8088825B2 (es) |
| EP (1) | EP1351672B1 (es) |
| JP (1) | JP4368579B2 (es) |
| KR (1) | KR100905335B1 (es) |
| CN (1) | CN1296039C (es) |
| AT (1) | ATE432071T1 (es) |
| AU (2) | AU2316202A (es) |
| BR (1) | BR0115527A (es) |
| CA (1) | CA2457925C (es) |
| DE (1) | DE60138834D1 (es) |
| ES (1) | ES2326159T3 (es) |
| MX (1) | MXPA03004427A (es) |
| NO (1) | NO20006008L (es) |
| NZ (1) | NZ525889A (es) |
| RU (1) | RU2259823C2 (es) |
| WO (1) | WO2002043728A1 (es) |
| ZA (1) | ZA200303668B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO328803B1 (no) | 2000-03-03 | 2010-05-18 | Thia Medica | Nye fettsyreanaloger |
| CN100351259C (zh) | 2002-06-20 | 2007-11-28 | Icvec有限公司 | 含硫的磷脂衍生物 |
| WO2005073164A1 (en) * | 2004-01-30 | 2005-08-11 | Peplin Biolipids Pty Ltd | Therapeutic and carrier molecules |
| MX2007000816A (es) * | 2004-07-19 | 2007-06-05 | Thia Medica As | Composicion que comprende material de proteina y compuestos que comprenden entidades de acido graso no oxidable. |
| AU2008274876A1 (en) * | 2007-02-05 | 2009-01-15 | Children, Youth And Women's Health Service | Modulators of antigen-dependent T cell proliferation |
| DE102011050519A1 (de) * | 2011-05-20 | 2012-11-22 | Universität Rostock | Alkylschwefelalkansäurederivate und ihre pharmazeutisch verträglichen Salze zur Behandlung chronisch entzündlicher Erkrankungen |
| CA2904898C (en) | 2013-03-11 | 2019-10-15 | Jan Remmereit | Lipid compositions containing bioactive fatty acids |
| HK1220606A1 (zh) | 2013-03-11 | 2017-05-12 | Nobesita As | 包含非可氧化脂肪酸的天然脂类 |
| EP3661600A4 (en) | 2017-10-23 | 2021-08-11 | Epitracker, Inc. | FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME |
| JP2021525249A (ja) | 2018-05-23 | 2021-09-24 | エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． | 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法 |
| WO2020146263A1 (en) | 2019-01-09 | 2020-07-16 | Epitracker, Inc. | Compositions and methods for diagnosis and treatment of neurodegenerative diseases |
| JP7404382B2 (ja) | 2019-03-04 | 2023-12-25 | エピトラッカー インコーポレイテッド | 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用 |
| WO2023080939A1 (en) | 2021-11-03 | 2023-05-11 | Epitracker, Inc. | Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56164120A (en) * | 1980-05-22 | 1981-12-17 | Chisso Corp | Antitumor agent |
| FR2631339B1 (fr) * | 1988-05-10 | 1990-11-16 | Cird | Nouveaux eicosanoides sulfures et leur application en pharmacie et en cosmetique |
| DE4120917A1 (de) | 1991-06-25 | 1993-01-07 | Basf Ag | Ester von fettsaeuren mit aminoalkoholen zur verwendung bei der bekaempfung von krankheiten |
| US5807884A (en) * | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| IL103932A (en) * | 1992-11-30 | 1997-02-18 | Yissum Res & Dev | Fatty acid and pharmaceutical compositions containing them |
| US5618955A (en) | 1992-11-30 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fatty acid derivatives and pharmaceutical compositions containing same |
| DE69524639T2 (de) * | 1994-10-13 | 2002-08-08 | Peptech Ltd., North Ryde | Modifizierte mehrfach ungesättigte fettsäuren |
| NO952796D0 (no) * | 1995-07-14 | 1995-07-14 | Rolf Berge | Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater |
| RU2089179C1 (ru) * | 1995-12-14 | 1997-09-10 | Закрытое акционерное общество "ВАМ" | Стимулятор эндогенной продукции цитокинов и гепопоэтических факторов и способ его использования |
| WO1997038688A1 (en) * | 1996-04-12 | 1997-10-23 | Peptide Technology Pty. Limited | Methods of treating immunopathologies using polyunsaturated fattyacids |
| IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
| WO1999058120A1 (en) * | 1998-05-08 | 1999-11-18 | Rolf Berge | USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS |
| AUPQ291499A0 (en) * | 1999-09-17 | 1999-10-07 | Women's And Children's Hospital Adelaide | Novel nitro and sulphur containing compounds |
-
2000
- 2000-11-28 NO NO20006008A patent/NO20006008L/no not_active Application Discontinuation
-
2001
- 2001-11-27 US US10/416,378 patent/US8088825B2/en not_active Expired - Fee Related
- 2001-11-27 KR KR1020037007097A patent/KR100905335B1/ko not_active Expired - Fee Related
- 2001-11-27 RU RU2003115423/15A patent/RU2259823C2/ru not_active IP Right Cessation
- 2001-11-27 BR BR0115527-0A patent/BR0115527A/pt not_active IP Right Cessation
- 2001-11-27 EP EP01998347A patent/EP1351672B1/en not_active Expired - Lifetime
- 2001-11-27 JP JP2002545699A patent/JP4368579B2/ja not_active Expired - Fee Related
- 2001-11-27 ES ES01998347T patent/ES2326159T3/es not_active Expired - Lifetime
- 2001-11-27 NZ NZ525889A patent/NZ525889A/en unknown
- 2001-11-27 AT AT01998347T patent/ATE432071T1/de not_active IP Right Cessation
- 2001-11-27 AU AU2316202A patent/AU2316202A/xx active Pending
- 2001-11-27 WO PCT/NO2001/000470 patent/WO2002043728A1/en not_active Ceased
- 2001-11-27 CA CA2457925A patent/CA2457925C/en not_active Expired - Fee Related
- 2001-11-27 DE DE60138834T patent/DE60138834D1/de not_active Expired - Lifetime
- 2001-11-27 CN CNB018196969A patent/CN1296039C/zh not_active Expired - Fee Related
- 2001-11-27 MX MXPA03004427A patent/MXPA03004427A/es active IP Right Grant
- 2001-11-27 AU AU2002223162A patent/AU2002223162B2/en not_active Ceased
-
2003
- 2003-05-13 ZA ZA200303668A patent/ZA200303668B/en unknown
-
2011
- 2011-12-29 US US13/340,157 patent/US20120101161A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8088825B2 (en) | 2012-01-03 |
| NO20006008D0 (no) | 2000-11-28 |
| NO20006008L (no) | 2002-05-29 |
| US20050165103A1 (en) | 2005-07-28 |
| CA2457925C (en) | 2013-03-26 |
| AU2002223162B2 (en) | 2006-11-30 |
| ES2326159T3 (es) | 2009-10-02 |
| RU2259823C2 (ru) | 2005-09-10 |
| KR100905335B1 (ko) | 2009-07-01 |
| ZA200303668B (en) | 2004-01-30 |
| HK1073793A1 (en) | 2005-10-21 |
| WO2002043728A1 (en) | 2002-06-06 |
| JP2004514693A (ja) | 2004-05-20 |
| BR0115527A (pt) | 2003-09-23 |
| CA2457925A1 (en) | 2002-06-06 |
| KR20030055322A (ko) | 2003-07-02 |
| CN1633284A (zh) | 2005-06-29 |
| CN1296039C (zh) | 2007-01-24 |
| JP4368579B2 (ja) | 2009-11-18 |
| US20120101161A1 (en) | 2012-04-26 |
| EP1351672A1 (en) | 2003-10-15 |
| DE60138834D1 (de) | 2009-07-09 |
| NZ525889A (en) | 2004-10-29 |
| ATE432071T1 (de) | 2009-06-15 |
| AU2316202A (en) | 2002-06-11 |
| EP1351672B1 (en) | 2009-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03004427A (es) | Analogos de acido graso para el tratamiento de desordenes inflamatorios y autoinmunes. | |
| BG108806A (en) | IIb/IIIa CELL ADHESION INHIIBITORS, METHOD FOR THE PRODUCTION, PHARMACEUTCIAL COMPOSITION AND ADMINISTRATION THEREOF | |
| AU5756298A (en) | Attenuated salmonella strain used as a vehicle for oral immunization | |
| DE69429450D1 (de) | Die verwendung von angiotensin iii und seiner analoge für die gewebeheilung | |
| MY132924A (en) | Hematopoietic stimulation | |
| MXPA03002629A (es) | Analogos de acido graso para el tratamiento de enfermedades proliferativas de la piel. | |
| EP1153924A3 (en) | Substituted 1,3-oxathiolanes with antiviral properties | |
| SG131109A1 (en) | Muteins of tear lipocalin | |
| WO2004045592A3 (en) | Compounds and methods for increasing neurogenesis | |
| PT1075259E (pt) | Novos analogos gordos para o tratamento de diabetes | |
| CA2489270A1 (en) | A method of treating human skin and a skin care composition for use in such a method | |
| MXPA04006542A (es) | Composiciones bucales estables que contienen complejos de fosfopeptido de caseina y fluooruro. | |
| AU2000233235A1 (en) | Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase | |
| AU2003210053A1 (en) | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor | |
| EP0139534A3 (en) | Compositions for the prophylactic treatment of osteitis and osteomyelitis | |
| MXPA04006541A (es) | Composiciones bucales estables que contienen complejos de fosfopeptido de caseina y fluoruro. | |
| CA2401757A1 (en) | Novel fatty acid analogues | |
| DE69814109D1 (de) | 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga | |
| DE60016181D1 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| BR9912279A (pt) | Uso de uteroglobina humana recombinante no tratamento de condições inflamatórias e fibróticas | |
| GB0005743D0 (en) | Pharmaceutical compositions including alginates | |
| ATE454425T1 (de) | Bitumenzusammensetzung | |
| ES2057762T3 (es) | Composicion de caucho de silicona y su fabricacion. | |
| Chatagner et al. | Effect of DL-ethionine on the level of cystathionase in rat liver | |
| DE602004030617D1 (de) | Rekombinante anti-cd64-eta' immunotoxine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |